
    
      Approximately 50 subjects diagnosed with an incompetent saphenous vein will be randomized to
      either 1% STS or 3% STS solution delivered by the ClariVein system under ultrasound guidance.

      Study duration for individual study patients, including follow-up visits, is anticipated to
      be approximately 16 weeks.
    
  